Halozyme Therapeutics reported $1.15B in Loan Capital for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
DBV Technologies DBVT:US 0 0
Acadia Pharmaceuticals ACAD:US $ 0M 0M
Agios Pharmaceuticals AGIO:US $ 1.06M 0.78M
Alnylam Pharmaceuticals ALNY:US $ 677.72M 1.01M
Amarin AMRN:US $ 0M 0M
Amgen AMGN:US $ 35705M 305M
Aptinyx Inc APTX:US $ 24.5M 206K
Baxter International BAX:US $ 16278M 487M
Cara Therapeutics CARA:US $ 0 0
Cytokinetics CYTK:US $ 198.42M 1.34M
Eli Lilly And LLY:US $ 14692M 460.9M
Esperion Therapeutics ESPR:US $ 259.08M 402K
Halozyme Therapeutics HALO:US $ 1147.13M 359.03M
Intercept Pharmaceuticals ICPT:US $ 713.86M 3.03M
Intra Cellular Therapies ITCI:US $ 0M 0M
IONIS PHARMACEUT IONS:US $ 1248.4M 0.47M
JAZZ PHA JAZZ:US $ 5990M 2.87M
Mannkind MNKD:US $ 366.99M 8.14M
Nektar Therapeutics NKTR:US $ 0M 0M
Peregrine Pharmaceuticals PPHM:US $ 141.8M 0.13M
United Therapeutics UTHR:US $ 800M 0M